Expect few changes in the running of GE Healthcare, despite a change in leadership
Expect few changes in the running of GE Healthcare, despite a change in leadership.
Joe Hogan has taken over as president and CEO of the multinational company, replacing William Castell, who held the reins of GE Healthcare for a little more than a year in the wake of the merger of GE Medical Systems and Amersham Health. Hogan, the former president and CEO of GE Healthcare Technologies, known as GE Medical Systems prior to the merger, stepped into Castell's shoes July 6.
Hogan, a chief architect of the Amersham merger and long-time advocate of personalized healthcare, views his ascendancy as portending no dramatic changes for himself or the business. He will continue promoting the corporate vision of personalized medicine, which he has advocated since taking over GE Medical Systems in 1998.
Hogan will not install a successor at GE Healthcare Technologies. Instead he will run the Milwaukee-based business unit from his new digs in London. Reinaldo Garcia, current president of the unit's Global Diagnostic Imaging, will manage the day-to-day affairs of the imaging business. Garcia will report to Hogan, as will Peter Loescher, who has served as president and CEO of GE Healthcare Bio-Sciences since April 2004.
Time management - choosing when, where, and how much time to spend on different duties - will be his biggest challenge, Hogan said. But putting his stamp on the GE vision of personalized healthcare may be the most rewarding.
Hogan sees the biosciences business as the key to moving imaging diagnostics into personalized medicine, making it part of the drug discovery and drug delivery side of healthcare. For him personally, this will require a deep understanding of the biosciences business and its makeup.
"That's both a challenge and a joy, because I love the science, but I haven't had a huge amount of exposure to it," he said.
The adoption of personalized medicine will hinge on increasing the sensitivity and specificity of medical diagnostics so as to identify disease before the onset of physical symptoms. This may allow preventive care that will keep disease at bay.
The development of such technologies will be expensive and difficult, not only in research and development but in navigating the regulatory process. Companies developing products for personalized medicine will have to demonstrate their value. This will require clinical tests, which for the most part the industry has been able to avoid so far.
The FDA's 510(k) process, under which most imaging equipment is cleared for market, is oriented toward safety rather than efficacy. "Substantial equivalence" to devices already on the market is its cornerstone. Technologies aimed at changing the practice of medicine from therapy to prevention will have no such predecessors. Consequently, they will not qualify for 510(k) review, which means their developers will have to meet the burden of proving their clinical value as part of the PMA or premarket approval process.
This will bring up challenges and opportunities, Hogan said, that might be met by a sense of cooperation among vendors rather than competition.
"There might be areas where vendors should work together," Hogan said. "We may have to ask how do we show that (this class of) technology is effective."
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.